This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): UGP302
Description: UGP302 is a proprietary 33 amino acid peptide analog of calcitonin, designed to recaptitulate calcitonin's appetite suppressant activity without its effects on bone resorption. It is hypothesized to act by binding to the amylin receptor, slowing gastric emptying and promoting saiety.
In August 2012, Unigene and Nordic Bioscience announced, under the Companies' established Joint Development Vehicle (JDV), announced that the Companies' have designated UGP302 as the initial lead compound for furthe study in the treatment of Type 2 diabetes.
In May 2013, Unigene announced it has entered into an equity transfer and exclusive license agreement with Nordic Bioscience (Nordic) involving three proprietary metabolic peptide analogs for Type 2 diabetes, osteoarthritis and osteoporosis developed as part of a Joint Development Vehicle (JDV) established by both companies. Under the terms of the equity transfer and exclusive license agreement, Nordic has agreed to pay $1,000,000 for Unigenes ownership interest in the JDV. In accordance, Unigene has granted the now 100% Nordic owned JDV, an exclusive, royalty-bearing license to develop and commercialize products incorporating any of the three licensed analogs for the treatment of Type 2 Diabetes, osteoarthritis and...See full deal structure in Biomedtracker
Partners: Unigene Laboratories, Inc.
Additional information available to subscribers only: